Paper Details

  1. Home
  2. Paper Details

Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy.

Author: AlShaibaniAlFadel, AljurfMahmoud, AppelbaumFrederick, CarpenterPaul A, CiureaStefan Octavian, DeFilippZachariah, DevineSteven M, DholariaBhagirathbhai, El ChaerFiras, GrunwaldMichael R, HamadaniMehdi, HamiltonBetty K, HashmiShahrukh K, HoltzmanNoa G, IiGordon L Phillips, InamotoYoshihiro, JainTania, Kharfan-DabajaMohamed A, LiuHien D, MajhailNavneet, MannisGabriel, MohtyMohamad, NaglerArnon, OranBetul, PeralesMiguel-Angel, RodriguezCesar, SavaniBipin N, ShahNina, TallmanMartin S

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Practice GuidelineGuidelines and recommendations for the diagnosis and treatment of specific medical conditions in medical practice.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This review examines the use of hematopoietic cell transplantation (HCT) for treating newly diagnosed adults with acute myeloid leukemia (AML). The review recommends that HCT is a standard treatment for patients with intermediate to high-risk AML, with a preference for a more intense type of conditioning before the transplant. The use of a transplant from a half-matched relative (haploidentical) is preferred over a cord blood transplant if a fully matched donor is not available. The review also discusses the evolving role of HCT in the context of new treatments and monitoring for residual disease after the transplant.
Paper Details　
Original Abstract of the Article :
The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consisting of both transplant and nontransplant experts, was invited to develop clinic...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.bbmt.2020.09.020

データ提供：米国国立医学図書館（NLM）

Hematopoietic Cell Transplantation: A Lifeline for Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a serious disease, and finding effective treatment is a race against time, like a camel crossing a scorching desert. This research, like a beacon of hope in the midst of the desert, focuses on the role of hematopoietic cell transplantation (HCT) in treating AML. HCT is a complex procedure, but it offers a chance for long-term survival, especially for patients with high-risk AML. The researchers reviewed the evidence and provided recommendations for best practices in using HCT for AML treatment. They emphasized the importance of considering factors like donor type and conditioning regimen to optimize outcomes.

A New Dawn for AML Patients

The research highlights the value of HCT as a treatment option for AML, especially for patients with intermediate- and high-risk disease. It provides guidance for clinicians on how to make informed decisions about treatment strategies.

A Camel's Perspective on AML

As a camel, I have a deep respect for the resilience of life. AML is a formidable opponent, like a relentless sandstorm. However, HCT offers a lifeline, like a hidden oasis, providing a chance for recovery and a return to health.

Dr.Camel's Conclusion

This evidence-based review provides valuable insights into the role of HCT in the management of AML. It highlights the importance of individualized treatment plans, informed decision-making, and ongoing research to improve outcomes for patients with AML.

Date :
  1. Date Completed 2021-07-02
  2. Date Revised 2023-11-29
Further Info :

Pubmed ID

32966881

DOI: Digital Object Identifier

10.1016/j.bbmt.2020.09.020

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.